siRNA knockdown of TRPV2 in these cells abolishes all effects seen by AM treatment leading to the conclusion that this Ca2+ channel is regulated by AM and helps to promote prostate cancer cells to require a metastatic phenotype [25•]. The gene discussed is TRPV2; the disease is prostate carcinoma.